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CLINICAL SCALES, CRITERIA AND TOOLS
Brazilian-Portuguese translation, 
cross-cultural adaptation and validation 
of the Myasthenia Gravis Composite scale. 
A multicentric study
Tradução,adaptação cultural e validação da escala composta de Miastenia Grave para a 
lingua portuguesa do Brasil. Estudo multicêntrico
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Myasthenia gravis (MG), a chronic autoimmune disease, 
is characterized by progressive weakness and fatigue of skel-
etal muscle caused, in 85% to 90% of patients, by antibodies 
against the acetylcholine receptor (AChR) of the post-synaptic 
membrane of the neuromuscular junction1. There is also a 
smaller number of patients showing autoantibodies against 
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ABSTRACT
Objective: To perform the translation, cultural adaptation and validation of the Myasthenia Gravis Composite (MGC) scale in Brazil. 
Methods: The study was conducted at three neuromuscular disease research centers in accordance with the international ethical 
standards, following a multi-modal approach and was conducted in three steps consisting of translation, cultural adaptation, and 
validation according to international guidelines. The final version of the MGC was applied in a sample of 27 MG patients and the total score 
was compared to a Portuguese version of the MG-QOL-15. Results: The internal consistency verified by Cohen’s Kappa test was excellent 
(0.766). The correlation between the MGC and MG-QOL-15 was strong (R = 0.777; p = 0.000). No significant differences were found between 
the responses of patients in the first and second applications of the MGC. Conclusion: The MGC scale, validated into Brazilian Portuguese, 
has proven to be a reliable instrument that is easy to use, and is highly reproducible. 
Keywords: myasthenia gravis; translating; surveys and questionaires.
RESUMO
Objetivo: Realizar a tradução e a adaptação transcultural da escala composta de Miastenia Grave (ECMG) Myasthenia Gravis Composite (MGC) 
no Brasil. Métodos:  O estudo foi realizado em três centros de investigação em doenças neuromusculares, de acordo com as normas éticas 
internacionais, consistindo em tradução, adaptação cultural e validação de acordo com as diretrizes internacionais. A versão final do MGC ECMG 
foi aplicada em vinte e sete pacientes com MG e a pontuação total foi comparada ao questionário MG-QOL 15. Resultados: A consistência interna 
verificada pelo teste Kappa de Cohen foi excelente (0,766) e a correlação entre o a ECMG MGC e MG-QOL 15 foi positiva (R = 0,777; p = 0,000). 
Não foram encontradas diferenças entre as respostas dos pacientes na primeira e segunda aplicação da MGC. Conclusão: A ECMG escala MGC 
validada para o Português do Brasil provou ser um instrumento confiável, de fácil aplicação e altamente reprodutível.
Palavras-chave: miastenia gravis; tradução; inquéritos e questionários.
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the muscle-specific kinase (MuSK) or the low-density lipo-
protein-related protein 4 (LRP4) and even against agrin2.
The prevalence of MG varies from 1.7 to 21.3 cases per 
million people per year in the general population, mainly 
affecting individuals aged 20-40 years, and more women than 
men (ratio 3:2). The mortality rate varies from 0.06 to 0.89 per 
million people each year3,4.
Disease severity depends on the compromised mus-
cle groups, varying from mild, with purely ocular symp-
toms, to the most serious cases with generalized mus-
cle weakness and respiratory failure1. The Myasthenia 
Gravis Committee Foundation of America (MGFA) cat-
egorizes MG into five levels of severity according to the 
appearance of symptoms and the anatomical distribu-
tion of affected muscle groups5.
Health Related Quality of Life (HRQoL) is an important 
component in the evaluation of MG patients, as the disease 
severity can vary widely. The assessment instruments of 
HRQoL and clinical progression can be generic or specific to 
a particular group of diseases, such as MG6. Clinical trials to 
test new therapeutic interventions require some scale of clin-
ical evaluation to assess the level of disease severity and the 
response to therapy7,8.
Information about clinical evaluation and HRQoL, 
obtained through specific instruments, enable a better 
understanding of the patient’s needs, and allow provision of 
adequate clinical support6. The more specific the instrument, 
the more relevant it becomes for evaluation and monitoring 
of disease progress.
The HRQoL and clinical status measures, obtained 
through patient-oriented instruments, are considered 
essential in the evaluation of neurological diseases, espe-
cially in those diseases that may affect a patient’s general 
status, such as MG. Patient-derived tools have added a 
new dimension to clinical outcome evaluation. These are 
important, both for assessing individual patients in the 
neurology clinic, and for international comparisons, mul-
ticenter trials and other types of collaborations9. Previous 
studies have described a significant correlation between 
HRQoL and severity of MG10,11,12.
We found only three specific tools for evaluating 
HRQoL in MG patients in the international scientific lit-
erature (Myasthenia Gravis Questionnaire13, Myasthenia 
Gravis-specific Activities of Daily Living Profile14,15, 
Questionnaire of Life Quality Specific for Myasthenia 
Gravis – 15 items (MG-QOL-15)16) and two instruments 
to assess the clinical evaluation of patients with MG 
(Quantitative Myasthenia Gravis Score17 and Myasthenia 
Gravis Composite scale (MGC)18). From these instru-
ments, only the MG-QOL-15 has been translated into 
Brazilian Portuguese19. Therefore, it was important to 
study the translation, cultural adaptation and validation 
of the MGC in Brazilian patients.
METHODS
The study was conducted at three neuromuscular dis-
ease research centers in accordance with the ethical stan-
dards established in the 1961 Declaration of Helsinki (as 
revised in Hong Kong in 1989 and Edinburgh, Scotland in 
2000) and complied with the Regulatory Guidelines and 
Norms for Research Involving Human Subjects of the 
National Health Board of the Brazilian Health Ministry 
issued in December 2012. This study is part of a research 
protocol that was approved by the Human Research Ethics 
Committee of Nove de Julho University (Brazil) under pro-
cess no. 360.488 and is registered with the World Health 
Organization (WHO) under Universal Trial Number (UTN) 
U1111-1147-7853 and the Brazilian Registry of Clinical 
Trials (REBEC) RBR -7ckpdd. A written informed con-
sent was obtained, and subjects were allowed to withdraw 
from the study at any time without consequence. 
The study included patients with a clinical diagnosis of 
MG according to the MGFA, aged 18–75 years, both genders, 
who were clinically stable and who agreed to participate by 
signing the informed consent form. We excluded patients 
with other neuromuscular disorders, episodes of acute clini-
cal decompensation in the two months prior to consider-
ation for inclusion, and those with a history of stroke, mental 
instability, or drug or alcohol abuse.  
The Instrument
The MGC scale is a valid and reliable instrument used 
to evaluate the clinical status of patients with MG both 
in clinical practice, and in scientific research. The scale 
was validated through tests conducted in 2008 and 2009 
in 11 research centers in the United States of America 
and Europe20. The MGC is an ordinal scale, consist-
ing of 10 items, each representing a function commonly 
affected by MG. The response categories of MGC items 
are weighted. For example, ‘ptosis’ scores 3 points, while 
‘severe weakness of hip flexion’ is equivalent to 5 points, 
and severe respiratory weakness (i.e. ventilator-dependent 
patients) equates to 9 points. The maximum MGC score 
is 50, and directly relates to patient condition i.e., a high 
score reflects severe disease. A reduction of 3 points in 
the score may indicate a significant and reliable clinical 
improvement in patients with MG.
Translation, cross-cultural adaptation, and 
validation
The study design followed a multi-modal approach and 
was conducted in three stages consisting of translation, cul-
tural adaptation, and validation of the MGC according to 
international guidelines proposed and developed in other 
linguistic and socio-cultural contexts21,22,23,24,25. Figure 1 dis-
plays the flowchart of the study.
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Translation
According to the established protocol previously pub-
lished26, two qualified Brazilian translators, one a professional 
scientific English translator who is unfamiliar with the area of 
expertise, the other a bilingual neurologist, performed inde-
pendent Brazilian Portuguese translations. Then, a committee 
of four neurologists and two physiotherapists, all bilingual, 
compared these two initial translations, creating a new, first 
version of the scale in Brazilian Portuguese. All members of this 
committee were bilingual university professors and research-
ers with clinical experience in neuromuscular diseases and 
had advanced knowledge of the English language.
Figure 1. Flow chart of the methodological approach.
Questionnaire in the original version
Committee – Evaluation of translated versions.
First version in Portuguese
Qualified translator Qualified translator
Reverse translation Reverse translation
Myasthenia Gravis Composite Scale
Translation into 
Brazilian Portuguese.
Translation into 
Brazilian Portuguese.
Native translator, 
not healthcare professional.
Native translator, 
healthcare professional.
Psychometric evaluation: reability and pre-test
Application in 20 patients with confirmed diagnosis of MG.
Psychometric evaluation: validation
Application of final version in 27 patients with MG.
Cross-cultural adaptation
Twnty professionals from clinical neurology 
and rehabilitation fields.
Expert Committee
Was compared to the original version, 
analyzed the discrepancies and generated 
the second version in Portuguese.
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Reverse-translation
Two native English speakers, a layperson and a professional 
translator, subsequently performed two reverse-translations 
of the preliminary Brazilian Portuguese version of the scale. 
These translators were not informed about the study objec-
tives and had no access to the original version. This reverse-
translation aimed to prove that the new version was equiva-
lent to the original. 
Another expert committee, comprising one methodolo-
gist, six health professionals, two native-speaking profession-
als and the translators, compared the two reverse-translation 
versions with the original English version of the MGC, made 
necessary adjustments, and generated the final version in 
Portuguese. The second Portuguese version of the scale was 
established after consensus was reached among committee 
members on each item.
Cross-cultural adaptation
The second version of the scale, translated into 
Portuguese, underwent a semantic analysis, and was ana-
lyzed by twenty health professionals, specializing in clinical 
neurology and rehabilitation medicine (10 physicians and 
10 physiotherapists), to determine whether the terms used 
were easy to understand. This step was performed to ensure 
that the translated items were equivalent to the original, and 
included an assessment of the degree of understanding of the 
issues proposed. 
Health professionals involved in this research phase made 
comments about the understanding of the scale. Any ambig-
uous terms were highlighted and discussed by the members 
of the study committee, and were replaced by other terms 
with semantic equivalence, appropriate to Brazilian culture, 
thereby generating a third version in Portuguese, without 
compromising the original version. 
Psychometric evaluation
Reliability
To check inter-rater reliability, the third Portuguese 
version was administered by 10 health professionals to 
20 patients with a confirmed diagnosis of MG (15 women), 
on two different occasions, at the same time of the day, with 
an interval of 48 hours, to assess test-retest reliability. These 
results were used to determine the level of semantic under-
standing to consolidate the final version of the MGC scale. 
The final version of the MGC scale translated into Brazilian 
Portuguese is presented in Figure 2.
Pre-test
The content validity was assessed qualitatively in a 
pilot study, in which the patients provided critical feedback 
on the design, content, and structure of the questionnaire, 
and in consultation with specialized clinicians in the field. 
The validity of the questions on the clinical characteristics 
and disease severity of MG were evaluated retrospectively 
by the two main investigators. They were blinded to the 
questionnaire results when registering the symptoms in 
the medical records of the 20 patients who participated in 
the pre-test stage. 
The self-reported clinical characteristics of the disease 
at onset were compared with the symptoms reported in the 
patient’s medical record, and the clinical symptoms reported 
in the medical records were considered to be the closest to a 
gold standard evaluation of the patients’ symptoms.
Validation
Forty patients (29 women) with a confirmed diagno-
sis of MG, and classified according to MGFA, were invited 
to participate in this step of the study. Twenty-seven 
patients (21 women) accepted, comprising 11 patients from 
Setor de Investigação de Doenças Neuromusculares da 
Universidade Federal de São Paulo (UNIFESP), 11 patients 
from Departamento de Neurologia da Faculdade de Ciências 
Médicas da Santa Casa de São Paulo (FCMSC), and five 
patients from Departamento de Neurologia do Hospital do 
Servidor Público Estadual (HSPE). 
Demographic and clinical data were collected, along 
with details of current MG-related symptoms and thera-
peutic strategies. We excluded nine patients due to cogni-
tive impairment, illiteracy and/or other chronic diseases 
and four patients because of a diagnosis of congenital 
myasthenic syndrome. The final version of the MGC was 
administered to in a final sample of 27 MG patients and 
the total score was compared to a Portuguese version of 
the MG-QOL-15, validated in Brazil, and commonly used 
to assess quality of life in MG19.
The MG-QOL-15 is an effective, quick, and easy-to-use 
instrument, consisting of 15 items, graded on a scale of 0-4, 
evaluating three dimensions of the HRQoL. The highest pos-
sible score is 60 points, indicating a poor quality of life as 
perceived by the patient. These 15 items efficiently evaluate 
physical, social, and psychological aspects of life, which are 
essential components for the interpretation of the HRQoL. 
The instrument does not have a specific cut-off value16,19.
Statistical analysis
Initially, the Shapiro-Wilk test was used to verify the 
normal distribution of the sample data. Parametric data 
were expressed as mean and standard deviation, including 
anthropometric values, age, and the circumferences of the 
neck and abdomen. Non-parametric data were expressed 
by standard error. 
In the pre-test, we used Cohen’s Kappa coefficient for 
ordinal measures. The Kappa statistic is frequently used to 
test inter-rater reliability. Rater reliability is important as it 
reflects the accuracy of the data collected. Measurement of 
the extent to which data collectors (raters) assign the same 
score to the same variable is called inter-rater reliability. 
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Pearson’s rank correlation coefficient was used for corre-
lation of the subjective assessment of MGC and MG-QOL 15. 
A p value < 0.05 was considered significant. Statistical anal-
yses were performed with the StatView 5.0 (SAS Institute, 
Cary, N.C., USA), and SPSS software (version 23.0, SPSS Inc. 
Chicago, IL, USA).
RESULTS
There were 27 patients (21 women) with a confirmed 
diagnosis of MG acquired autoimmune form, and a mean 
age of 46.55 ± 11.71 years, range 32–74 years, enrolled in this 
study. The average duration of illness in these patients was 
11.33 ± 8.49 years. According to the classification of MGFA, 
two patients were class I, 17 were class II, eight were class III, 
and none were in classes IV and V. Ninety-eight percent of 
patients were taking cholinesterase inhibitors and 28% were 
taking an immunosuppressant. Clinical and demographic 
features of the MG patients are presented in the Table.
Reliability and validity
The average time required for completing the MGC by 
patients was 32 minutes. The expression “ptosis, ascending 
naturally”, in the original version, was replaced by “ptosis, look-
ing up easily”. Items used in the evaluation of muscle strength 
of neck flexion/extension, hip flexion, and shoulder abduction 
generated the greatest difficulty. Specifically, the grading of 
muscle weakness as moderate weakness posed problems. The 
original version emphasizes that moderate weakness should 
Nota: Observe que “fraqueza moderada” para os itens pescoço e membros deve ser interpretada como fraqueza equivalente a 50%±15% do esperado para uma 
força normal. Qualquer fraqueza mais leve do que isto seria classificada como leve e qualquer fraqueza mais grave seria classificada como grave.
Total de pontos: ______________________
Figure 2. Portuguese-Brazil version of Myasthenia Gravis Composite Scale.
Ptose (olhar para cima 
facilmente) > 45 segundos 11–45 segundos 1–10 segundos Imediata
(exame médico) 0 1 2 3
Visão dupla (olhar fixo 
lateral) (esquerda ou 
direita).
> 45 segundos 11–45 segundos 1–10 segundos Imediata
 (exame médico) 0 1 3 4
Fechamento dos olhos Normal Fraqueza leve (abertura com esforço externo) Fraqueza moderada Fraqueza grave
(exame médico)
0 0 (podem ser abertos facilmente)
(incapaz de manter os 
olhos fechados)
    1 2
Fala Normal Gagueira intermitente ou fala nasal
Gagueira constante ou 
fala nasal que pode ser 
compreendida
Dificuldade no 
entendimento da fala
(História do paciente) 0 2 4 6
Mastigação Normal Fadiga com alimentos sólidos
Fadiga com alimentos 
moles Tubo gástrico
(História do paciente) 0 2 4 6
Deglutição Normal
Raros episódios de 
engasgo ou dificuldade 
para engolir = 2
Dificuldade frequente 
na deglutição com 
necessidade de alteração 
na dieta
Tubo gástrico
(História do paciente) 0   5 6
Respiração Normal Dispneia de esforço Dispneia em repouso Ventilador dependente 
(consequência da MG) 0 2 4 9
Flexão ou extensão de 
pescoço. Normal Fraqueza leve Fraqueza moderada Fraqueza grave
(exame médico) 0 1 (~50% fraca ± 15%) = 3 4
Abdução de ombros Normal Fraqueza leve Fraqueza moderada Fraqueza grave
(exame médico) 0 2 (~50% fraca ± 15%) = 4 5
Flexão do quadril Normal Fraqueza leve Fraqueza moderada Fraqueza grave
(exame médico) 0 2 (~50% fraca ± 15%) = 4 5
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be equal to approximately 50% ± 15% of the expected normal 
force. Accordingly, we added a note explaining how to grade 
moderate muscle weakness to the final version of the scale.
The internal consistency verified by Cohen’s Kappa 
test was excellent (0.766). Patients scored an average of 
12.93 ± 6.92 in the MGC scale and an average of 21.38 ± 12.07 
in the MG-QOL-15 scale. The correlation between the MGC 
and MG-QOL-15 was strong (R = 0.777; p = 0.000). No sig-
nificant differences were found between the responses of 
patients in the first and second applications of the MGC.
DISCUSSION
In recent years, disease-specific, patient-derived question-
naires have become important measures to describe disease sever-
ity when compared with generic, patient-derived instruments.
According to our knowledge, this is the first study of the 
translation and validation of the MGC scale to a language 
other than English. Translation of the MGC to Brazilian 
Portuguese was successful, and reverse-translation to English 
corresponded very well with the original version. The MGC 
scale was properly translated and culturally adapted follow-
ing a defined sequence of actions in accordance with the 
standards for cultural adaptation21,22,23,24,25. 
In 2012, a Task Force of the Medical Scientific Advisory 
Board of the MGFA recommended using the MGC as the 
quantitative measure for determining improvement or dete-
rioration in patients with generalized MG27.
The MGC can be used in daily practice and in clinical tri-
als. This instrument differs from most scales in that it is a 
hybrid of patient-reported and physician-reported test items. 
It is not surprising that certain patient-reported test items 
perform better than their physician-reported examination 
counterparts, and thus justify inclusion in the MGC.  
The validity and reliability of the MGC for measuring dis-
ease severity in MG was previously demonstrated using con-
ventional psychometric tests28,29.
The evaluation of the HRQoL of a patient can influence 
therapeutic decisions and provide a better understanding of 
their needs, allowing the adoption of an appropriate thera-
peutic strategy16,30. A disease-specific instrument may be the 
most relevant clinical and functional assessment of the dis-
ease state, avoiding ineffective approaches28. 
In the validation phase, the Brazilian version of the MGC 
was very well understood and accepted by patients and 
by health professionals. Neither patients nor professionals 
had difficulties completing the questionnaire. In the valida-
tion phase of our study, the MGC was compared with the 
MG-QOL-15, considered the gold standard HRQoL assess-
ment instrument in MG, with a positive correlation. This 
result corroborates other studies that validated the use of the 
MGC as an evaluation tool in patients with MG16,18.
Factors related to the disease can influence HRQoL in 
MG, such as the predominant symptoms, the frequency of 
myasthenic crisis and the therapeutic strategy adopted. The 
frequency and severity of MG symptoms also influence the 
perception of HRQoL. Therefore, it is expected that a poor 
clinical situation will lead to a poor HRQoL result.
In conclusion, the original version of the MGC scale, having 
been translated, culturally adapted, and validated into Brazilian 
Portuguese has proven to be a reliable instrument that is easy to 
use, highly reproducible, and can be used in both clinical prac-
tice and clinical trials in the evaluation of patients with MG. 
Table. Clinical and demographic features of the patients with 
myasthenia gravis.
Variables Patients (n = 27) (%)
Female/male 21/jun - 
Age (years) 46.55 ± 11.71  -
Disease classification
Acquired autoimmune 27  -
MGFA
I 2 7.4
IIA 15 55.5
IIB 2 7.4
IIIA 4 14.8
IIIB 4 14.8
MGC score 12.8 ± 7  -
MG QOL – 15 score 21.7 ± 12.2  -
MGFA: Myasthenia Gravis Foundation of America Clinical classification; 
MGC: Mysthenia Gravis Composite scale; MG-QOL: Questionnaire of Life 
Quality Specific for Myasthenia Gravis – 15 items.
References
1. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-810.
2. Patrick J, Lindstrom J. Autoimmune response to 
acetylcholine receptor. Science. 1973;180(4088):871-2. 
doi:10.1056/NEJM199406233302507
3. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic 
review of population based epidemiological studies in Myasthenia 
Gravis. BMC Neurology. 2010;10(1):46. doi:10.1186/1471-2377-10-46
4. Mao ZF, Mo XA, Qin C, Lai YR, Hartman TCO. Course and prognosis 
of myasthenia gravis: a systematic review. Eur J Neurol. 
2010;17(7):913-21. doi:10.1111/j.1468-1331.2010.03017.x
5. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey 
JC, Penn ASet al. Myasthenia gravis: recommendations 
for clinical research standards. Ann Thorac Surg. 
2000;70(1):327-34. doi:10.1016/S0003-4975(00)01595-2
920 Arq Neuropsiquiatr 2016;74(11):914-920
6. Cella DF, Tulsky DS. Measuring quality of life today: methodological 
aspects. Oncology (Willinston Park). 1990;4(5):29-38. 
7. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells 
L, Belendiuk G. Preliminary results of a double-blind, 
randomized, placebo-controlled trial of cyclosporine in 
myasthenia gravis. N Engl J Med. 1987;316(12):719-24. 
doi:10.1056/NEJM198703193161205
8. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical 
therapeutic trial of cyclosporine in myasthenia gravis. 
Ann N Y Acad Sci. 1993;681 1 Myasthenia GR:539-51. 
doi:10.1111/j.1749-6632.1993.tb22937.x
9. Tonali P, Padua L, Sanguinetti C, Padua R, Romanini E,  
Amadio P. Outcome research and patient-oriented measures  
in the multiperspective assessment of neurological and 
musculoskeletal disorders. Consensus Conference:  
Third Roman Neurophysiology Day, Outcome Research  
in Neurology and in Musculoskeletal Disorders – 24  
October 1998. Ital J Neurol Sci. 1999;20(2):139-40. 
doi:10.1007/s100720050022
10. Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio 
F et al. Concordance between severity of disease, disability and 
health-related quality of life in myasthenia gravis. Neurol Sci. 
2010;31(1):41-5. doi:10.1007/s10072-009-0167-y
11. Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio 
F et al. The relationship between health, disability and quality of 
life in myasthenia gravis: results from an Italian study. J Neurol. 
2010;257(1):98-102. doi:10.1007/s00415-009-5279-z
12. Morris J, Perez D, McNoe B. The use of quality of life 
data in clinical practice. Qual Life Res. 1998;7(1):85-91. 
doi:10.1023/A:1008893007068
13. Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C et al. 
Myasthenia gravis outcome measure: development and validation 
of a disease-specific self-administered questionnaire. Neurol Sci. 
2002;23(2):59-68. doi:10.1007/s100720200027
14. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn 
RJ. Myasthenia gravis activities of daily living profile. Neurology. 
1999;22;52(7):1487. doi:10. 1212/ WNL. 52. 7. 1487  
15. Muppidi S. The myasthenia gravis: specific activities of 
daily living profile. Ann N Y Acad Sci. 2012;1274(1):114-9. 
doi:10.1111/j.1749-6632.2012.06817.x
16. Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and 
concurrent validation of the MG-QOL15 in the practice setting. 
Muscle Nerve. 2010;41(2):219-6. doi:10.1002/mus.21609
17. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, 
Fateh-Moghadam A. Myasthenia gravis: long-term correlation 
of binding and bungarotoxin blocking antibodies against 
acetylcholine receptors with changes in disease severity. Neurology. 
1983;33(10):1316-21. doi:10.1212/WNL.33.10.1316
18. Burns TM, Conaway MR, Cutter GR, Sanders DB Construction 
of an efficient evaluative instrument for myasthenia gravis: 
the MG composite. Muscle Nerve. 2008;38(6):1553-62. 
doi:10.1002/mus.21185
19. Mourão AM, Araújo CM, Barbosa LS, Gomez RS, Burns TM, Lemos 
SM et al. Brazilian cross-cultural translation and adaptation 
of the “Questionnaire of Life Quality Specific for Myasthenia 
Gravis - 15 items”. Arq. Neuropsiquiatr. 2013;71(12):955-58. 
doi:10.1590/0004-282X20130180
20. Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM. Psychometric 
evaluation of the myasthenia gravis composite using Rasch analysis. 
Muscle Nerve. 2012;45(6):820-5. doi:10.1002/mus.23260
21. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation 
of health-related quality of life measures: literature review and 
proposed guidelines. J Clin Epidemiol. 1993;46(12):1417-32. 
doi:10.1016/0895-4356(93)90142-N
22. Guillemin F. Cross-cultural adaptation and validation of 
health status measures. Scand J Rheumatol. 1995;24(2):61-3. 
doi:10.3109/03009749509099285
23. Reichenheim ME, Moraes CL. Operationalizing the cross-
cultural adaptation of epidemological measurement 
instruments. Rev Saúde Pública. 2007;41(4):665-73. 
doi:10.1590/S0034-89102006005000035
24. Maher CG, Latimer J, Costa LOP. The relevance of cross-
cultural adaptation and clinimetrics for physical therapy 
instruments. Rev Bras Fisioter. 2007;11(4):245-52. 
doi:10.1590/S1413-35552007000400002
25. Beaton D, Bombardier C, Guillemin F, Ferraz MB. Guidelines for 
process of cross-cultural adaptation of self-report measures. Spine. 
2000;(25)24:3186-91. doi:10.1097/00007632-200012150-00014
26. Oliveira EF, Urbano JJ, Santos IR, Silva AS, Guimarães LL, Peixoto RAO 
et al. Brazilian translation, cross-cultural adaptation and validation 
of the MG Composite scale and Quantitative Myasthenia gravis 
testing form: a multicentric study protocol. Man Ther Posturology 
Rehabil J. 2016;14:1-5. doi:10.17784/mtprehabjournal.2016.14.342
27. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F et al. 
Recommendations for myasthenia gravis clinical trials. Muscle 
Nerve. 2012;45(6):909-17. doi:10.1002/mus.23330
28. Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 
Study Group. The MG Composite. A valid and reliable outcome 
measure for myasthenia gravis. Neurology. 2010;74(18):1434-40. 
doi:10.1212/WNL.0b013e3181dc1b1e
29. Burns TM. The MG composite: an outcome measure for myasthenia 
gravis for use in clinical trials and everyday practice. Ann N Y Acad 
Sci. 2012;1274(1):99-106. doi:10.1111/j.1749-6632.2012.06812.x
30. Morris J, Perez D, McNoe B. The use of quality of life 
data in clinical practice. Qual Life Res;1998;7(1):85-91. 
doi:10.1023/A:1008893007068
